Section 3 of 6
Product information and disease description
297 evidence topics · 146 sources
Product description
Phase of product development
Investigational status
Investigational new drug application
Initiation of the Himalayas-1 Phase 3 trial
Himalayas-1 registry status and dates
| Registry field | Quoted record |
|---|---|
| Overall status | “Recruiting” |
| Study start (actual) | “2026-08-03” |
| Primary completion (estimated) | “2028-03” |
| Study completion (estimated) | “2030-09” |
License from Mirati Therapeutics
Expedited program designations
No evidence found.
Regulatory status
No evidence found.
Launch
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Manufacturer: ORIC Pharmaceuticals
Proposed international nonproprietary name
Recommended international nonproprietary name
Brand name
No evidence found.
Dosage forms and strengths
Phase 3 dose in the Himalayas-1 registry record
Pharmaceutical form and unit strengths
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
AHFS classification
No evidence found.
Indication
Investigated indication in the Himalayas-1 Phase 3 trial
Required prior abiraterone and excluded prior therapies
Labeled indications of darolutamide, the combination partner
Combination with apalutamide in the Phase 1b trial
Pipeline entry for a second Phase 3 trial with apalutamide
Pharmacology
Mechanism of action
Allosteric inhibition of PRC2 through the EED subunit
Company rationale for targeting EED rather than EZH2
Rationale for combination with androgen receptor pathway inhibition
Pharmacodynamics
H3K27me3 reduction in peripheral blood with single-agent dosing
H3K27me3 reduction in combination with darolutamide
Plasma cell-free DNA methylation in participants treated with single-agent rinzimetostat
Paired tumor biopsies in participants treated with single-agent rinzimetostat
Preclinical synergy with androgen receptor pathway inhibitors
Preclinical chromatin and lineage effects
Preclinical single-agent activity in an enzalutamide-resistant model
Preclinical activity in EZH2 inhibitor-resistant settings
Nonclinical toxicology: hematologic tumorigenesis in rats
Pharmacokinetics
Clinical half-life as reported in January 2024
Estimated half-life by single-agent dose level as reported in April 2024
Clinical half-life as reported in February 2026
Exposure by dose level
Food effect with darolutamide
Preclinical solubility, oral bioavailability, and half-life
| Property | Rinzimetostat |
|---|---|
| Solubility | “11.7 mg/ml” |
| Mouse oral bioavailability | “64%” |
| Mouse half-life, oral | “3-5 hr PO” |
| Mouse half-life, intravenous | “2.5 hr IV” |
| Clinical half-life | “~20 hrs” |
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Himalayas-1 protocol: age, performance status, and organ function
Himalayas-1 protocol exclusion: brain metastases
Himalayas-1 protocol exclusion: cardiovascular disease, recent radiotherapy, and gastrointestinal disease
Phase 1b protocol exclusion: viral infection
Phase 1b protocol exclusion: malabsorption and central nervous system metastases
Renal impairment: darolutamide, the combination partner
Hepatic impairment: darolutamide, the combination partner
Geriatric use: darolutamide, the combination partner
Males of reproductive potential: darolutamide, the combination partner
Drug/Drug, drug/disease interactions
Effects of other drugs on Rinzimetostat
Coadministration with darolutamide
Effects of other drugs on darolutamide, the combination partner
Darolutamide metabolism and clinical interaction studies
Effects of Rinzimetostat on other drugs
In vitro CYP inhibition and induction
| Assay | Enzymes | Result |
|---|---|---|
| CYP inhibition | “CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4” | “IC50 >10 µM” |
| CYP induction | “CYP1A2, CYP2B6, CYP3A4 (1 µM)” | “<2X of vehicle control; <20% of positive control” |
Effects of darolutamide, the combination partner, on other drugs
Dosing and administration
Dosage
Recommended Phase 3 dose with darolutamide
Exposure-response analysis supporting dose selection
Provisional doses with darolutamide and with apalutamide
Administration
Administration with or without food in Himalayas-1
Access and distribution
Access through clinical trials before approval
Expanded access policy
Co-prescribed/Concomitant therapies
Darolutamide: class and labeled indications
Darolutamide: recommended dosage and concurrent androgen deprivation
Darolutamide: dosage modification for adverse reactions
Darolutamide: warnings and precautions
Darolutamide: dosage form and package
Darolutamide: wholesale acquisition cost filing with the California Department of Health Care Access and Information
| Field | Quoted record |
|---|---|
| Manufacturer name | “Bayer” |
| National drug code | “50419039501” |
| Drug product description | “Nubeqa 300 mg tab 120 count” |
| WAC effective date | “2026-01-01T00:00:00” |
| WAC increase amount (USD) | “847.20” |
| WAC after increase (USD) | “15100.80” |
Darolutamide supply for Himalayas-1 under the Bayer agreement
Continued androgen deprivation therapy in the rinzimetostat trials
Effect of Rinzimetostat on quality measures
Bone density evaluation during androgen deprivation therapy: CMS645v9 and MIPS Quality ID 462
Enhancing Oncology Model: prostate cancer episodes
Product comparison
Mevrometostat plus enzalutamide: randomized phase 1 dose expansion after abiraterone
Mevrometostat plus enzalutamide: dose escalation after abiraterone or enzalutamide
Mevrometostat 875 mg with food plus enzalutamide: safety and selection of the phase 3 dose
Mevrometostat 875 mg with food plus enzalutamide: efficacy after abiraterone, enzalutamide naive
Mevrometostat plus enzalutamide: MEVPRO-1 and MEVPRO-2 phase 3 designs
“MEVPRO-1 ( NCT06551324 ) is an open-label, phase III trial which will evaluate mevrometostat plus enzalutamide versus physician’s choice of either enzalutamide or docetaxel in patients with mCRPC who have progressed following ≥12 weeks of treatment with abiraterone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomization will be stratified by previous docetaxel in the metastatic castration-sensitive prostate cancer (mCSPC) setting, physician’s choice of comparator (prespecified prior to randomization and will remain consistent throughout the study), and presence of hepatic metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MEVPRO-2 ( NCT06629779 ) is a double-blind, placebo-controlled, phase III trial that will evaluate mevrometostat plus enzalutamide versus enzalutamide alone in adult patients with mCRPC who are treatment-naïve” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary efficacy endpoint for both MEVPRO-1 and MEVPRO-2 is rPFS per RECIST 1.1 (soft tissue) and PCWG3 (bone) assessed by BICR. OS (alpha protected) is a key secondary endpoint in both studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There will be no interim analysis for the primary endpoint (rPFS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mevrometostat plus enzalutamide: MEVPRO-1 enrollment and estimated primary completion
Mevrometostat plus enzalutamide: MEVPRO-3 in metastatic castration-sensitive disease
Tazemetostat plus enzalutamide: CELLO-1 randomized phase 2 after abiraterone
Tazemetostat: market withdrawal for hematologic second primary malignancies
Class concern for hematologic malignancy with chronic PRC2 inhibition in prostate cancer
“Mevrometostat, valemetostat, and tulmimetostat ( 18 – 20 ) have now been evaluated in several hundred patients. To date, no comparable secondary-malignancy signal has been publicly reported for these agents. This experience is reassuring but not yet definitive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the phase 1/2 mevrometostat experience, median follow-up was approximately 9.6 months as of the September 2, 2024 data cut ( 21 ) substantially shorter than the interval over which therapy-related MDS/AML typically emerge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All of these factors are possible mediators of risk, though no published data currently link any specific pharmacologic property to differential second-malignancy risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CPI-1205 plus enzalutamide or abiraterone: ProSTAR phase 1b/2
Company benchmark comparison: landmark rPFS and safety versus mevrometostat after abiraterone
| Regimen | Median follow-up | Month 3 rPFS | Month 4 rPFS | Month 5 rPFS | Grade 3 or higher TRAEs | Dose reductions / discontinuations |
|---|---|---|---|---|---|---|
| Mevrometostat 875 mg twice daily fed plus enzalutamide (n=14) | “9.2” months | “92%” | “92%” | “84%” | “36%” | “7% / 7%” |
| Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41) | “11.7” months | “92%” | “86%” | “80%” | “49%” | “37% / 2%” |
| Enzalutamide monotherapy (n=40) | “9.0” months | “78%” | “70%” | “60%” | “23%” | “8% / 5%” |
| Rinzimetostat 400 mg once daily plus darolutamide (n=18) | “4.9” months | “93%” | “84%” | “84%” | “6%” | “None / 6%” |
Company benchmark comparison: serious adverse events and dose modifications versus mevrometostat
| Measure | Mevrometostat 875 mg twice daily fed plus enzalutamide (n=14) | Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41) | Rinzimetostat 400 mg once daily plus darolutamide (n=18) |
|---|---|---|---|
| Grade 3 or higher TRAEs | “36%” | “49%” | “6%” |
| Serious TRAEs | “21%” | “24%” | “None” |
| Dose reductions | “7%” | “37%” | “None” |
| Treatment discontinuations | “7%” | “2%” | “6%” |
Company comparison of rPFS across post-ARPI therapies
| Treatment | Status | Month 5 rPFS | Median rPFS, months |
|---|---|---|---|
| Enzalutamide | “Approved” | “60%” | “6.2” |
| Cabazitaxel | “Approved” | “65%” | “8.0” |
| Docetaxel | “Approved” | “75%” | “8.3” |
| Lutetium Lu 177 vipivotide tetraxetan | “Approved” | “75%” | “9.3” |
| Mevrometostat plus enzalutamide | “Phase 3” | “80% to 84%” | “~12 to 14” |
| Rinzimetostat plus darolutamide | “Starting”“Phase 3” | “84% to 85%” | “Not mature” |
Company statements comparing dose optimization results with mevrometostat
Company comparison of PRC2 inhibitor development status
| Product | Development status |
|---|---|
| CPI-1205 | “Discontinued” |
| Tazemetostat | “Discontinued” |
| Mevrometostat | “Phase 3 trials ongoing” |
| Rinzimetostat | “First Phase 3 initiation expected 1H 2026” |
Company preclinical claims for EED targeting: EZH1 coverage and acquired resistance
Company preclinical claims for hematologic tumorigenesis in rat toxicology versus tazemetostat
Place of product in therapy
Disease description
Definition and etiology
Definition of castration-resistant prostate cancer
Castrate testosterone threshold in clinical trials
“PCWG3 retains the definition of castrate as ≤ 50 ng/dL of testosterone (or ≤ 0.50 ng/mL or 1.73 nmol/L) but encourages investigators to consider using ultrasensitive testosterone assays with a sensitivity to 1 to 2 ng/dL when evaluating a drug known or suspected to change androgen levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical states model and lines of prior therapy
“Considers mCRPC in terms of number of lines of prior therapy rather than in relation to docetaxel treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“replacing the pre- versus postchemotherapy distinction with a dynamic classification that considers the lines of therapy a patient has received independent of the mechanism of action, the order in which they were administered, and the sensitivity of the tumor to each” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology of castration resistance: continued androgen receptor signaling
“It is now accepted that castration-resistant prostate cancer is not androgen-independent and continues to rely on androgen signaling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An abundance of data acquired since then, however, has made it overwhelmingly clear that residual androgens remaining after castration and AR itself remain central both to the progression to CRPC and to its continued growth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression from prostate cancer to castration resistance
“Together, the data indicate that 10-20% of prostate cancer patients develop CRPC within approximately 5 years of follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Together, ≥ 84% were shown to have metastases at diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
Estimated U.S. new cases in 2026, all prostate cancer stages
| Measure | Quoted value |
|---|---|
| Estimated new cases of prostate cancer, United States, 2026 | “333,830”View highlighted excerpt for this quote |
U.S. incidence rate, all prostate cancer stages
Distant-stage disease at diagnosis, all prostate cancer
| SEER measure | Quoted value |
|---|---|
| Percentage of cases diagnosed at distant stage | “9%” |
U.S. incidence trend of regional-stage and distant-stage prostate cancer
“From 2014 through 2022, the prostate cancer incidence rate rose by 2.9% per year (Table 5), with a longer and steeper slope for regional‐stage (4.6% per year since 2013) and distant‐stage (5.6% per year since 2011) disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modeled U.S. annual incidence of metastatic castration-resistant prostate cancer, 2009 and 2020
“The model estimated the prevalence of prostate cancer as 2,219,280 in the US in 2009 and 3,072,480 in 2020, and incidence of mCRPC as 36,100 and 42,970, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority (86%) of incidence flow into mCRPC states was from the nmCRPC clinical state.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Newly diagnosed metastatic castration-resistant prostate cancer in Medicare fee-for-service, 2014 to 2019
“Men newly diagnosed with mCRPC were identified in Medicare fee-for-service claims during 1/1/2014–6/30/2019.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The final study population consisted of 14,780 men” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company estimate: U.S. annual incidence of metastatic castration-resistant prostate cancer after abiraterone
Prevalence of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
U.S. prevalence in 2023, all prostate cancer stages
Modeled U.S. prevalence of metastatic castration-resistant prostate cancer by clinical state, 2009 and 2020
| Clinical state | Prevalence, 2009 | Prevalence, 2020 projection |
|---|---|---|
| Asymptomatic or minimally symptomatic mCRPC not treated with or not progressed on chemotherapy | “6745”View highlighted excerpt for this quote | “8320”View highlighted excerpt for this quote |
| Symptomatic mCRPC not treated with or not progressed on chemotherapy | “32,145”View highlighted excerpt for this quote | “39,650”View highlighted excerpt for this quote |
| mCRPC that progressed on or after first-line chemotherapy | “23,220”View highlighted excerpt for this quote | “28,720”View highlighted excerpt for this quote |
Metastatic disease among men living with prostate cancer, modeled U.S. estimate for 2009
Prior androgen receptor pathway inhibitor before metastatic castration-resistant prostate cancer, U.S. Flatiron cohort 2016 to 2023
“Before mCRPC diagnosis, most patients (73.9% [3963/5361]) had not received treatment intensification; 867 (16.2%) had received prior ARPi only; 448 (8.4%), prior taxane only; and 83 (1.5%), both prior ARPi and taxane.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The use of ARPi-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over the study course, the majority (76.8%) of patients received an ARPi as 1L treatment for mCRPC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prior abiraterone for metastatic hormone-sensitive disease and androgen receptor pathway inhibitor reuse, U.S. ConcertAI cohort 2020 to 2023
“Among 609 people identified, the most common prior treatment for mHSPC was androgen deprivation therapy (ADT) alone (53%); others included ADT plus abiraterone (ABI; 19%), ADT plus a non-ABI androgen receptor pathway inhibitor (ARPI; 18%) and ADT plus docetaxel (10%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among those who received ADT plus ABI or a non-ABI ARPI for mHSPC, 50% and 40%, respectively, also received an ARPI 1L for mCRPC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prior novel hormonal therapy and sequential novel hormonal therapy, Medicare fee-for-service cohort 2014 to 2019
“Ten per cent of patients had undergone NHT use prior to their mCRPC diagnosis, and 3% had previously been treated with taxane-based chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Androgen receptor pathway inhibitor sequencing across real-world studies
Natural history, survival, and mortality
Progression to metastatic castration-resistant disease as the cause of prostate cancer death
Modeled share of U.S. prostate cancer deaths occurring in metastatic castration-resistant states
Estimated U.S. deaths in 2026, all prostate cancer stages
| Measure | Quoted value |
|---|---|
| Estimated deaths from prostate cancer, United States, 2026 | “36,320”View highlighted excerpt for this quote |
U.S. prostate cancer mortality trend, all stages
“Increased incidence also may be contributing to a deceleration in the decline for prostate cancer mortality, from 3.5% per year during the late 1990s and 2000s to 0.6% per year from 2012 through 2023 (Table 8, Figure 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distant-stage five-year relative survival, all metastatic prostate cancer
| SEER measure | Quoted value |
|---|---|
| Distant-stage five-year relative survival | “40.1%” |
Overall survival in metastatic castration-resistant prostate cancer, U.S. Flatiron cohort 2016 to 2023
Overall survival in metastatic castration-resistant prostate cancer, Medicare fee-for-service cohort 2014 to 2019
“Overall mortality in the cohort was 54%. Median survival from mCRPC diagnosis was 25.6 months (95% confidence interval [CI] 25.0–26.2 months) (Fig. 3). Median survival from treatment initiation was 23.4 months (95% CI: 22.8–24.1 months)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall survival in metastatic castration-resistant prostate cancer after metastatic hormone-sensitive disease, U.S. ConcertAI cohort 2020 to 2023
“Median real-world overall survival was 27.2 months from mCRPC diagnosis and 20.8 months from 1L therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Back-to-back ARPI use from mHSPC to mCRPC is common in current clinical practice and survival remains <3 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world overall survival across observational studies
Overall survival after an androgen receptor pathway inhibitor and a taxane, standard-of-care arm of a phase 3 trial
“The median overall survival among all 831 patients who had undergone randomization was 15.3 months in the 177Lu-PSMA-617 group, as compared with 11.3 months in the control group (hazard ratio for death, 0.62; 95% CI, 0.52 to 0.74; P<0.001 [significance level, 0.05])” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall survival by site of metastasis, docetaxel-treated trial participants
“Men with liver metastases had the worst median OS (13.5 months). Although men with lung metastases had better median OS (19.4 months) compared with men with liver metastases, they had significantly worse median survival duration than men with nonvisceral bone metastases (21.3 months). Men with LN-only disease had a median OS of 31.6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival with castration-resistant prostate cancer before current therapies
Pathophysiology
Androgen receptor signaling as the driver of castration resistance
“Over the past ten years, preclinical studies implicating sustained androgen receptor (AR) signaling as the primary driver of castration resistant prostate cancer (CRPC) led to the development of novel agents targeting the AR pathway that are now in widespread clinical use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this review, we highlight emerging mechanisms of acquired resistance to these contemporary therapies, which fall into the three broad categories of restored AR signaling, AR bypass signaling and complete AR independence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Androgen receptor pathway alterations in metastatic biopsies
“In aggregate 107/150 (71.3%) of cases harbored AR pathway aberrations, the majority of which were direct alterations affecting AR through amplification and mutation (Fig. 4A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The high frequency of AR pathway alterations in this cohort strongly implies that the vast majority of mCRPC affected individuals remain dependent on AR signaling for viability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary and acquired resistance to androgen receptor pathway inhibitors
“Although enzalutamide and abiraterone represent breakthroughs in the treatment of metastatic castration-resistant prostate cancer, approximately 20 to 40% of patients have no response to these agents with respect to prostate-specific antigen (PSA) levels (i.e., they have primary resistance).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who initially have a response to enzalutamide or abiraterone, virtually all eventually acquire secondary resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Androgen receptor splice variant 7 and cross-resistance to enzalutamide and abiraterone
“The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among men receiving enzalutamide, AR-V7–positive patients had lower PSA response rates than AR-V7–negative patients (0% vs. 53%, P = 0.004)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, among men receiving abiraterone, AR-V7–positive patients had lower PSA response rates than AR-V7–negative patients (0% vs. 68%, P = 0.004)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Androgen receptor bypass through the glucocorticoid receptor
“Recent work reveals a novel AR pathway resistance mechanism analogous to one originally described for kinase inhibitors, in which signaling downstream of the targeted kinase is restored by activation of a related kinase not targeted by the inhibitor” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lineage plasticity and neuroendocrine differentiation after androgen receptor pathway inhibitors
“With the growing clinical use of abiraterone and enzalutamide, it is increasingly appreciated that some men can relapse with clinically aggressive variants of PCa with reduced or absent AR expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate cancer involves epithelial plasticity, wherein tumor cells demonstrate low to absent AR expression and often neuroendocrine features.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EZH2 expression in castration-resistant neuroendocrine prostate cancer
PRC2 and EZH2 inhibition restoring antiandrogen sensitivity in preclinical models
“Ezh2 is the enzymatic component of the Polycomb Repressive complex 2 that methylates the lysine 27 residue of histone H3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinically relevant Ezh2 inhibitors restore androgen receptor expression and sensitivity to antiandrogen therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EZH2 as an androgen receptor coactivator in castration-resistant cells
“Here we report that the oncogenic function of EZH2 in castration-resistant prostate cancer (CRPC) is independent of its role as a transcriptional repressor. Instead, it involves the ability of EZH2 to act as a co-activator for critical transcription factors including the androgen receptor (AR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
PSA progression criteria in clinical trials
“After decline from baseline: record time from start of therapy to first PSA increase that is ≥ 25% and ≥ 2 ng/mL above the nadir, and which is confirmed by a second value ≥ 3 weeks later (ie, a confirmed rising trend)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Soft-tissue and nodal progression criteria in clinical trials
“PCWG3 recommends that lymph nodes that were previously normal in size (< 1.0 cm) or pathologic in size must have grown by at least 5 mm in the short axis from baseline or nadir and be ≥ 1.0 cm in the short axis to be considered to have progressed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imaging and laboratory assessment in castration-resistant disease
Imaging cadence in clinical trials
“To minimize patient exposure to ineffective treatment, and to better assess the timing of the antitumor effects of an agent for which the optimal timing is not known, an 8- to 9-week assessment interval for the first 6 months and every 12 weeks thereafter is advised.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PSMA PET imaging before PSMA-targeted radioligand therapy
“Documentation of PSMA expression in metastatic sites is required prior to the initiation of RLT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The diagnostic accuracy of PSMA-ligand PET/CT for bone assessment was superior to that of bone scan” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Germline and somatic genomic testing
“Patients with metastatic prostate cancer should undergo both germline and somatic DNA sequencing using panel-based assays. These tests can guide the use of poly(ADP-ribose) polymerase inhibitors, which have a survival benefit in metastatic castration-resistant prostate cancer.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Biochemical presentation: rising PSA before imaging or symptoms
Skeletal symptoms: bone pain from bone metastases
Urinary symptoms: obstruction from local tumor growth
Constitutional symptoms: weight loss and fatigue
Pattern of metastatic spread at diagnosis of castration resistance
Long-term morbidity
Skeletal complications of bone metastases in castration-resistant disease
Skeletal-related events and symptomatic skeletal events as defined for trials
“PCWG2 did not consider skeletal-related events (SREs), which include asymptomatic nonclinical fractures ascertained by serial imaging, clinical pathologic fractures, spinal cord compression, and surgery or radiation therapy to bone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PCWG3 advises reporting SSEs that include only symptomatic events of clear clinical significance, in contrast to SREs, which also include asymptomatic fractures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Skeletal-related events without bone-targeted therapy, placebo arm of a randomized trial
“A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median time to first skeletal-related event was 321 days for patients who received placebo” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Skeletal-related events by type during bone-targeted therapy in metastatic castration-resistant prostate cancer
| First on-study skeletal-related event | Zoledronic acid (n=951) | Denosumab (n=950) |
|---|---|---|
| Total confirmed events | “386 (41%)”View highlighted excerpt for this quote | “341 (36%)”View highlighted excerpt for this quote |
| Radiation to bone | “203 (21%)”View highlighted excerpt for this quote | “177 (19%)”View highlighted excerpt for this quote |
| Pathological fracture | “143 (15%)”View highlighted excerpt for this quote | “137 (14%)”View highlighted excerpt for this quote |
| Spinal cord compression | “36 (4%)”View highlighted excerpt for this quote | “26 (3%)”View highlighted excerpt for this quote |
| Surgery to bone | “4 (<1%)”View highlighted excerpt for this quote | “1 (<1%)”View highlighted excerpt for this quote |
Cumulative incidence of skeletal-related events after diagnosis of bone metastasis, U.S. health systems
“SREs were present at diagnosis of bone metastasis in 22.4, 22.4, and 10.0 % of BC, LC, and PC patients, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In BC, cumulative incidence of SREs during follow-up was 38.7 % at 6 months, 45.4 % at 12 months, and 54.2 % at 24 months; in LC, it was 41.0, 45.4, and 47.7 %; and in PC, it was 21.5, 30.4, and 41.9 %.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Skeletal-related events and survival, SEER-Medicare men with prostate cancer metastatic to bone
“Among 3,297 men with prostate cancer metastatic to bone, 40% experienced ≥1 SRE (median follow-up, 19 months). Compared with men who remained SRE-free, men with ≥1 SRE had a twofold higher risk for death (HR, 2.29; 95% CI, 2.09–2.51). Pathological fracture was associated with the highest risk for death (HR, 2.77; 95% CI, 2.38–3.23).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
Humanistic burden and health-related quality of life
Patient-reported impact on daily life: multinational survey
“A total of 221 patients with mCRPC and 159 caregivers from USA, France, Germany, Canada, Spain, China, and Brazil were surveyed. mCRPC impacts mood, emotional and mental health (50–77%), sleep (48–68%), career goals (48–80%), and social activities (46–65%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients face high treatment and pill burden (7–12 pills/day) and prefer simpler treatment regimens.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For many patients (52% to 73%), ≥9 hours per week were devoted to mCRPC care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One in three patients experiences fatigue, which is persistent and happens during day-to-day activities (Figure 2(b)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world deterioration of health-related quality of life and pain
“In total, 151 included patients answered 873 questionnaires.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At inclusion, generic HRQoL was high with a mean EQ visual analog score of 73.2 out of 100. The lowest scores were reported on role and physical functioning (mean scores of 69 and 76 of 100, respectively), and fatigue, pain, and insomnia were the most impaired domains. These domains deteriorated in > 50% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“mCRPC has a negative impact on HRQoL with deterioration in all domains over time, especially role and physical functioning.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health state utility values by disease state
“Data were collected from a total sample of 163 men with metastatic CRPC. Utility values elicited by the EQ-5D-5L ranged from 0.830 for the asymptomatic/mildly symptomatic before chemotherapy disease state (95% confidence interval [CI] 0.795-0.865) to 0.625 for the symptomatic before chemotherapy disease state (95% CI 0.577-0.673).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“EORTC-8D utilities ranged from 0.856 (95% CI 0.831-0.882) to 0.697 (95% CI 0.664-0.731) for the same disease/treatment states.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled health state utility values by line of therapy: meta-analysis
“In primary studies, baseline EQ-5D index utility values ranged from 0.7 to 0.9 in 1L and 0.63 to 0.7 in 2L+.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled mean baseline EQ-5D index utility value was estimated as 0.79 (95% CI, 0.70–0.84) and 0.69 (95% CI, 0.67–0.71) for 1L (n = 7 studies) and 2L + (n = 4 studies), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled mean baseline EQ VAS score was estimated as 74.63 (95% CI, 70.97–78.29) and 65.82 (95% CI, 64.53–67.11) in 1L and 2L+, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time to worsening after progression on one androgen receptor pathway inhibitor
“Eligible patients had metastatic castration-resistant prostate cancer, were candidates for ARPI change after one progression on a previous ARPI” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the [177Lu]Lu-PSMA-617 versus ARPI change groups, median time to worsening in FACT-P total score was 7·46 months (95% CI 6·08-8·54) versus 4·27 months (3·45-4·50; hazard ratio [HR] 0·61 [95% CI 0·50-0·75]), in EQ-5D-5L utility score was 6·28 months (4·70-7·89) versus 3·88 months (3·25-4·44; 0·67 [0·54-0·82]), and in BPI-SF pain intensity was 5·03 months (4·40-6·80) versus 3·65 months (3·09-4·37; 0·72 [0·59-0·88]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“median time to first symptomatic skeletal event was not reached (95% CI not estimable [NE]-NE) in the [177Lu]Lu-PSMA-617 group versus 17·97 months (14·26-NE) in the ARPI change group (HR 0·41 [0·26-0·63]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pain progression with a second androgen receptor pathway inhibitor after docetaxel
“Pain response was observed in 51 (46%) of 111 patients with cabazitaxel and 21 (19%) of 109 patients with abiraterone or enzalutamide (p<0·0001). Median time to pain progression was not estimable (NE; 95% CI NE-NE) with cabazitaxel and 8·5 months (4·9-NE) with abiraterone or enzalutamide (hazard ratio [HR] 0·55, 95% CI 0·32-0·97; log-rank p=0·035).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median time to FACT-P total score deterioration was 14·8 months (95% CI 6·3-NE) with cabazitaxel and 8·9 months (6·3-NE) with abiraterone or enzalutamide (HR 0·72, 95% CI 0·44-1·20; log-rank p=0·21).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pain, skeletal events, and health-related quality of life after taxane and androgen receptor pathway inhibitor
“Pain in patients with mCRPC can be attributed largely to bone metastases, lumbosacral invasion, and nerve root compression, and is associated with shortened OS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Time to worsening was delayed in the 177Lu-PSMA-617 plus SoC group (n = 385) versus SoC alone (n = 196) for FACT-P total score (HR, 0·46; 95% CI: 0·35, 0·61) and subdomains, BPI-SF pain intensity score (HR, 0·45; 95% CI: 0·33, 0·60) and EQ-5D-5L utility score (HR, 0·49; 95% CI: 0·40, 0·62).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SSEs occurred in 60/385 patients (16%) in the 177Lu-PSMA-617 group and 34/196 patients (17%) in the control group (table 2). The predominant types of SSE were radiation to relieve bone pain, followed by spinal cord compression (table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Cost increase at progression to castration resistance
“Among 296 patients with mCSPC progressing to mCRPC (median age 69.0 years, 60.5% White, 15.9% Black)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean number of days with PC-related outpatient visits increased from 1.57 to 2.16 PPPM in the mCSPC and mCRPC disease states (P < 0.001). From the mCSPC to mCRPC disease states, mean all-cause total health care costs PPPM increased from $4,424 (medical costs: $2,846) to $9,717 (medical costs: $4,654), and mean PC-related total health care costs PPPM increased from $2,859 (medical costs: $1,626) to $8,012 (medical costs: $3,285; all P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs during first-line therapy: commercial, Medicare Advantage, and Medicaid claims
“Among 459 patients with mCRPC (mean age 70 years, 57% White, 16% Black, 45% commercially-insured, 43% Medicare Advantage-insured, and 12% Medicaid-insured), average baseline all-cause total costs (PPPM) were $4,576 ($4,166 pre-mCRPC progression, $8,278 post-mCRPC progression).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During an average 1 L duration of 8.5 months, mean total costs were $13,746 (all-cause) and $12,061 (PC-related) PPPM.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PC-related medical costs PPPM increased from $1,504 during baseline to $5,585 following 1 L mCRPC therapy initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare fee-for-service resource use by line of therapy
“A total of 14,780 men with mCRPC were identified. After mCRPC diagnosis, 11,528 men initiated 1L mCRPC therapy, 6275 initiated 2L, and 2945 initiated 3L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All-cause medical HRU (days PPPY) increased after mCRPC diagnosis and from 1L through 3L treatment, particularly for outpatient care (pre-diagnosis, 10.4; 1L, 16.2; 2L, 18.9; 3L, 22.0) and physician/other visits (pre-diagnosis, 30.1; 1L, 46.5; 2L, 50.2; 3L, 56.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After mCRPC diagnosis, 11,528 (78%) patients received life-prolonging therapy and 3252 (22%) patients did not.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare fee-for-service costs by line of therapy
| Period | All-cause medical and pharmacy, mean per patient per year (2019 USD) | Prostate cancer-related medical, mean per patient per year (2019 USD) |
|---|---|---|
| Year before mCRPC diagnosis | “27,468”View highlighted excerpt for this quote | “11,411”View highlighted excerpt for this quote |
| After mCRPC diagnosis, all patients | “124,379”View highlighted excerpt for this quote | “52,609”View highlighted excerpt for this quote |
| After diagnosis, no life-prolonging therapy | “102,380”View highlighted excerpt for this quote | “51,076”View highlighted excerpt for this quote |
| First line | “148,325”View highlighted excerpt for this quote | “69,063”View highlighted excerpt for this quote |
| Second line | “160,118”View highlighted excerpt for this quote | “73,467”View highlighted excerpt for this quote |
| Third line | “165,186”View highlighted excerpt for this quote | “95,240”View highlighted excerpt for this quote |
Older Medicare beneficiaries: resource use and costs per patient-year
“A total of 4758 patients met the eligibility criteria and received 1L treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On average, patients had 1.2 inpatient admissions, 1.1 emergency room visits, and 27.6 outpatient visits per year during follow-up. The mean total all-cause and PC-related costs during the follow-up period were $111,060 and $99,540 per-patient-per-year, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Second androgen receptor pathway inhibitor or taxane after a first: resource use in Medicare
“Patients with mCRPC who previously received one androgen receptor pathway inhibitor (ARPI) followed by either a second ARPI (ARPI cohort) or a taxane (taxane cohort) were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 923 patients, 714 were in the ARPI cohort and 209 in the taxane cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was ≈1 year in both cohorts. SAEs were more frequent in the taxane cohort (66.0% vs 42.2%; p < 0.001). The taxane cohort had more ER, outpatient, and pharmacy visits (p < 0.0001), while the ARPI cohort had more hospitalizations (p < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Taxane adverse event costs after first-line androgen receptor pathway inhibitor
“Overall, 2L ARPI (n = 473) vs. taxane (n = 214) was associated with longer median OS (15.4 vs. 13.6 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients receiving > 8 vs. ≤ 8 taxane cycles were also more likely to experience an AE (95% vs. 88%) but had lower mean AE-related total healthcare costs per patient per month ($3,429 vs. $6,334).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, only 22% of patients in the Flatiron cohort and 13% in the PharMetrics cohort received > 8 cycles of taxanes, while 78% and 87%, respectively, were early discontinuers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insurer drug payments by first-line agent: employer-sponsored insurance
“This retrospective cohort study included 4,298 patients with prostate cancer who initiated therapy with one of six drugs approved for first-line treatment of mCRPC between July 1, 2013, and June 30, 2019.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over the 6 months after the index prescription, mean unadjusted gross drug payments were highest for patients receiving sipuleucel-T ($115,525 USD) and lowest for patients using docetaxel ($12,804 USD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Skeletal-related events: attributable Medicare cost
“HCRU and costs (in 2013 U.S. dollars) were evaluated in a propensity score-matched cohort by using Poisson regression and Kaplan-Meier sample average estimators, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 3,297 men with prostate cancer metastatic to bone, 40% experienced ≥1 SRE (median follow-up, 19 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among men with ≥1 SRE, emergency department visits were twice as frequent (95% CI, 1.77–2.28) and hospitalizations were nearly four times as frequent (95% CI, 3.20–4.40). The attributable cost of ≥1 SRE was $21,191 (≥1 SRE: $72,454 [95% CI, $67,362–$76,958]; SRE-free: $51,263 [95% CI, $45,439–$56,100]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide on families
Caregiver time, finances, and employment
“Caregivers often spouses or partners, provide practical, financial, and emotional support, averaging 11 hours/week of providing care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the majority of caregivers (58% to 60%), providing care affects their finances (60%), sleep (60%), energy level (59%), mood/mental health (58%), and overall day-to-day life (58%). More than half of caregivers (53%) report an impact on their ability to work.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 79% of caregivers who worked outside the home before their patient’s mCRPC diagnosis, 40% reduced their working hours, 13% stopped working completely, 3% retired as planned, and 43% made other changes; only 15% continued working normally post-diagnosis (Supplementary Table S1). Among those who reduced work hours, 64% reduced their hours by half or more.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of high financial toxicity and coping behaviors
“Overall, 281 patients met inclusion criteria of which 79 reported high financial toxicity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with high financial toxicity were more likely to decrease spending on basic goods (35% vs 2.5%, P < .001) and leisure activities (59% vs 15%, P > .001), as well as use savings (62% vs 17%, P < .001) to pay for their treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Indirect costs and the role of informal caregivers
“Qualitative descriptions were congruent with quantitative items assessing indirect costs of treatment, with many patients describing alterations to work, early retirement, and caregiver lifestyle changes (Quotes 1.2.2, 1.2.3, 1.2.5). Additional indirect costs not evaluated by the quantitative assessment included the opportunity cost of time spent navigating insurance coverage, as well as costs of travel to treatment sites, including gas, commute time, hotel expenses, and even relocating to be closer to care (Quotes 1.2.2, 1.2.4, 1.2.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, how treatment costs impacted the lives of patients’ loved ones was a strong contributor to the degree of financial stress that they experienced (Quotes 3.3.3, 3.3.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket payments for oral androgen receptor pathway inhibitors under Medicare Part D
“There were 4,153 patients who filled abiraterone or enzalutamide through Medicare Part D in 228 hospital-referral regions. Mean adherence was 75%. Median monthly out-of-pocket payment for abiraterone and enzalutamide was $706 (range $0 to $3,505).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket payments by first-line agent: employer-sponsored insurance
“OOP payments were lower than gross drug payments; mean 6-month OOP payments were highest for cabazitaxel ($1,044 USD) and lowest for docetaxel ($296 USD). There was a wide distribution of OOP payments within drug types.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Genetic testing rates before PARP inhibitor approval: United States oncology records
“Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 in 2013 to 313 in 2018 (out of 3161 and 3010 clinically active patients, respectively). Receiving care in an academic oncology center (versus a community-based center) strongly predicted genetic testing (hazard ratio = 2.41).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Biomarker testing rates in metastatic prostate cancer: United States community oncology network
“For these metastatic subgroups, biomarker testing rates were 80% (NSCLC), 34% (prostate), and 42% (bladder). Median time from disease diagnosis to first test order was 10 days (NSCLC), 98 days (prostate), and 23 days (bladder), with differences observed across racial and ethnic groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among tested patients, actionable mutations were identified in 29% (NSCLC), 25% (prostate), and 14% (bladder) of patients, and targeted therapy was received by 54%, 15%, and 38% of these patients, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genomic testing rates and BRCA yield: Dutch registry
Tissue availability for somatic genomic testing
“A total of 150 pts were enrolled. All had germline and initial ctDNA testing. Results from tissue testing were available in 72 pts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sequencing results from tissue were available in only half of pts, highlighting the challenges of obtaining tumor tissue for genomic testing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Genomic test-directed olaparib: United States payer model
“Olaparib yielded an additional 0.063 and 0.068 of quality-adjusted life year (QALY) with the augmented cost of $7,382 and saved the cost of $ 1,980 compared to standard care in scenario A and B, respectively, which yielded an ICER of $116,903/QALY and a cost-saving option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Included the NGS cost ($5,800).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Germline BRCA testing-guided olaparib: Australian payer model
“Compared to standard care, BRCA testing-guided olaparib treatment was associated with an incremental cost of AU$7,841 and a gain of 0.06 quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio (ICER) was AU$143,613 per QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Germline BRCA testing with cascade testing of relatives: Australian payer model
“Compared with no testing, BRCA testing in mPCa was associated with an incremental cost of AU$3731 and a gain of 0.014 quality-adjusted life-years (QALYs), resulting in an incremental cost-effectiveness ratio of AU$265 942/QALY. Extending testing to FDRs of variant-positive patients resulted in an incremental cost-effectiveness ratio of AU$16 392/QALY.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost per PSMA PET scan used in a United States model
| Imaging input | Cost (2021 USD) |
|---|---|
| Piflufolastat F 18 PET | “6274.17”View highlighted excerpt for this quote |
| Gallium 68 PSMA-11 PET | “6036.17”View highlighted excerpt for this quote |
| Fluciclovine F 18 PET | “6336.17”View highlighted excerpt for this quote |
| Computed tomography | “241.90”View highlighted excerpt for this quote |
PSMA PET cost-effectiveness in biochemical recurrence: United States model
“PSMA-PET had mean increments of $99 000 (95% UI, $55 000-153,000) in costs and 0.58 QALYs (95% UI, 0.35-0.82 QALYs) compared with CTBS, leading to an ICER of $172 000 per QALY, which exceeded the assumed $150 000/QALY willingness-to-pay threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study found that PSMA-PET may be associated with improved disease detection but may not be cost-effective due to high treatment costs offsetting moderate improvements in QALYs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PSMA PET cost-effectiveness: systematic review
“A total of seven studies were examined, representing both private and public healthcare systems. Overall, these studies demonstrate high methodological and reporting quality. When compared to existing imaging technologies or standard care practices, PSMA-PET/CT or MRI is cost-effective within country-specific willingness-to-pay thresholds.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Androgen deprivation therapy
Continued castration in metastatic castration-resistant disease: guideline statements
Continued castration in hormone-refractory disease: treatment summary
Concurrent gonadotropin-releasing hormone analog or orchiectomy in androgen receptor pathway inhibitor labeling
Continued androgen deprivation in post-inhibitor trials
Androgen receptor pathway inhibitors
Enzalutamide: FDA-approved indications
Abiraterone acetate: FDA-approved indications
Apalutamide: FDA-approved indications
Darolutamide: FDA-approved indications
Guideline statements on sequencing androgen receptor pathway inhibitors
Randomized crossover trial of abiraterone and enzalutamide sequences
“Primary endpoints were time to second PSA progression and PSA response (≥30% decline from baseline) on second-line therapy, analysed by intention-to-treat in all randomly assigned patients and in patients who crossed over, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PSA responses to second-line therapy were seen in 26 (36%) of 73 patients for enzalutamide and three (4%) of 75 for abiraterone (χ2 p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Enzalutamide showed activity as a second-line novel androgen receptor pathway inhibitor, whereas abiraterone acetate did not, leading to a longer time to second PSA progression for the sequence of abiraterone followed by enzalutamide than with the opposite treatment sequence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Single-arm study of enzalutamide after abiraterone
“Multicentre, single-arm, open-label study, enrolled patients with progressing mCRPC after ≥24 wk of abiraterone acetate plus prednisone treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median radiographic progression-free survival was 8.1 mo (95% confidence interval: 6.1-8.3); median overall survival had not been reached.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Unconfirmed PSA response rate was 27% (48 of 181).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adding enzalutamide to abiraterone at PSA progression on enzalutamide: PLATO
“Median progression-free survival was 5.7 months in the combination group and 5.6 months in the control group (hazard ratio, 0.83; 95% CI, 0.61 to 1.12; P = .22).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PLATO also reported limited benefit with abiraterone after enzalutamide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, results from PLATO suggest that enzalutamide should not be continued in combination with abiraterone after PSA progression during enzalutamide monotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Second inhibitor after docetaxel and one inhibitor: CARD control arm
“The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling-targeted inhibitor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P = 0.008).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Change of inhibitor in taxane-naive disease: PSMAfore control arm
“Eligible patients were adults with PSMA-positive mCRPC who were candidates for a change of ARPI following one instance of disease progression on abiraterone, enzalutamide, darolutamide, or apalutamide as their most recent anticancer therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At third data cut-off after 334 rPFS events, the updated hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·49 (95% CI, 0·39–0·61); the median rPFS was 11·60 months (95% CI, 9·30–14·19) vs 5·59 months (4·21–5·95)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At third data cut-off, the proportion of patients with confirmed prostate-specific antigen (PSA) decline of at least 50% from baseline was higher with 177 Lu-PSMA-617 vs ARPI change (51% [95% CI, 43·8–57·5] vs 17% [12·6–22·9])” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the ARPI change group, the median duration of exposure was 6·52 months (IQR, 7·77); 100 patients received abiraterone and 132 patients received enzalutamide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Second inhibitor as control in BRCA-altered disease: TRITON3
Taxane and platinum chemotherapy
Docetaxel: FDA-approved indication and TAX327 overall survival
| Outcome | Docetaxel plus prednisone every 3 weeks | Mitoxantrone plus prednisone every 3 weeks |
|---|---|---|
| Median survival, months (95% CI) | “18.9 (17.0-21.2)” | “16.5 (14.4-18.6)” |
| Hazard ratio (95% CI) | “0.761 (0.619-0.936)” | Not applicable |
Docetaxel: TAX327 publication
“As compared with the men in the mitoxantrone group, men in the group given docetaxel every three weeks had a hazard ratio for death of 0.76 (95 percent confidence interval, 0.62 to 0.94; P=0.009 by the stratified log-rank test)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among these three groups, 32 percent, 45 percent, and 48 percent of men, respectively, had at least a 50 percent decrease in the serum PSA level (P<0.001 for both comparisons with mitoxantrone)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cabazitaxel: FDA-approved indication and TROPIC overall survival
| Outcome | Cabazitaxel plus prednisone | Mitoxantrone plus prednisone |
|---|---|---|
| Median survival, months (95% CI) | “15.1 (14.1-16.3)” | “12.7 (11.6-13.7)” |
| Hazard ratio (95% CI) | “0.70 (0.59-0.83)” | Not applicable |
Cabazitaxel: TROPIC publication
“At the cutoff for the final analysis (Sept 25, 2009), median survival was 15·1 months (95% CI 14·1-16·3) in the cabazitaxel group and 12·7 months (11·6-13·7) in the mitoxantrone group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common clinically significant grade 3 or higher adverse events were neutropenia (cabazitaxel, 303 [82%] patients vs mitoxantrone, 215 [58%]) and diarrhoea (23 [6%] vs one [<1%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cabazitaxel versus a second androgen receptor pathway inhibitor after docetaxel: CARD
| Outcome | Cabazitaxel plus prednisone or prednisolone plus G-CSF | Abiraterone plus prednisone or prednisolone, or enzalutamide |
|---|---|---|
| Median rPFS, months (95% CI) | “8.0 (5.7 to 9.2)” | “3.7 (2.8 to 5.1)” |
| rPFS hazard ratio (95% CI) | “0.54 (0.40 to 0.73)” | Not applicable |
| Median OS, months (95% CI) | “13.6 [11.5; 17.5]” | “11.0 [9.2; 12.9]” |
| OS hazard ratio (95% CI) | “0.64 [0.46; 0.89]” | Not applicable |
Cabazitaxel versus a second androgen receptor pathway inhibitor: CARD publication
“Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling-targeted inhibitor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“tumor response was noted in 36.5% and 11.5% (P = 0.004)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statements on chemotherapy after androgen receptor pathway inhibitors
Platinum chemotherapy: guideline treatment-selection factors
Carboplatin added to cabazitaxel: randomized phase 2 trial
“At a median follow-up of 31·0 months (IQR 20·5–37·1), the combination improved the median progression-free survival from 4·5 months (95% CI 3·5–5·7) to 7·3 months (95% CI 5·5–8·2; hazard ratio 0·69, 95% CI 0·50–0·95, p=0·018).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the phase 2 study, the most common grade 3–5 adverse events were fatigue (7 [9%] of 79 in the cabazitaxel group vs 16 [20%] of 81 in the combination group), anaemia (3 [4%] vs 19 [23%]), neutropenia (3 [4%] vs 13 [16%]), and thrombocytopenia (1 [1%] vs 11 [14%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PARP inhibitors
Olaparib monotherapy: FDA-approved indication after enzalutamide or abiraterone
Olaparib monotherapy: PROfound efficacy, cohort A
| Outcome | Olaparib (n=162) | Enzalutamide or abiraterone acetate (n=83) |
|---|---|---|
| Median rPFS, months (95% CI) | “7.4 (6.2, 9.3)” | “3.6 (1.9, 3.7)” |
| rPFS hazard ratio (95% CI) | “0.34 (0.25, 0.47)” | Not applicable |
| Median OS, months (95% CI) | “19.1 (17.4, 23.4)” | “14.7 (11.9, 18.8)” |
| OS hazard ratio (95% CI) | “0.69 (0.50, 0.97)” | Not applicable |
Olaparib monotherapy: PROfound primary publication
“We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In cohort A, imaging-based progression-free survival was significantly longer in the olaparib group than in the control group (median, 7.4 months vs. 3.6 months; hazard ratio for progression or death, 0.34; 95% confidence interval, 0.25 to 0.47; P<0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Anemia and nausea were the main toxic effects in patients who received olaparib.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Olaparib monotherapy: PROfound overall survival publication
“The median duration of overall survival in cohort A was 19.1 months with olaparib and 14.7 months with control therapy (hazard ratio for death, 0.69; 95% confidence interval [CI], 0.50 to 0.97; P = 0.02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In cohort B, the median duration of overall survival was 14.1 months with olaparib and 11.5 months with control therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 86 of 131 patients (66%) in the control group crossed over to receive olaparib (56 of 83 patients [67%] in cohort A).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rucaparib: FDA-approved indication after androgen receptor-directed therapy
Rucaparib: TRITON3 efficacy, BRCA-mutated subgroup
| Outcome | Rucaparib (N=201) | Androgen receptor pathway inhibitor or docetaxel (N=101) |
|---|---|---|
| Median rPFS, months (95% CI) | “11.2 (9.2-13.8)” | “6.4 (5.4-8.3)” |
| rPFS hazard ratio (95% CI) | “0.50 (0.36, 0.69)” | Not applicable |
| Median OS, months (95% CI) | “23.2 (19.1, 25.2)” | “21.2 (18.0, 23.1)” |
| OS hazard ratio (95% CI) | “0.91 (0.68, 1.20)” | Not applicable |
| Overall response rate, % (95% CI) | “45.1 (34.1, 56.5)” | “17.1 (7.2, 32.1)” |
Rucaparib: TRITON3 crossover and ATM subgroup
Rucaparib: TRITON3 comparisons with docetaxel and with a second inhibitor
“In the BRCA subgroup, the median duration of imaging-based progression-free survival was longer with rucaparib than with docetaxel (11.2 months vs. 8.3 months; hazard ratio, 0.53; 95% CI, 0.37 to 0.77)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the median duration was also longer with rucaparib than with abiraterone acetate or enzalutamide (11.2 months vs. 4.5 months; hazard ratio, 0.38; 95% CI, 0.25 to 0.58)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statements on PARP inhibitors in pretreated disease
First-line combination in inhibitor-naive disease: olaparib with abiraterone
| Outcome (BRCA-mutated subgroup, exploratory) | Olaparib plus abiraterone (N = 47) | Placebo plus abiraterone (N = 38) |
|---|---|---|
| Median rPFS, months (95% CI) | “NR (NR, NR)” | “8 (6, 15)” |
| rPFS hazard ratio (95% CI) | “0.24 (0.12, 0.45)” | Not applicable |
| Median OS, months (95% CI) | “NR (NR, NR)” | “23 (18, 34)” |
| OS hazard ratio (95% CI) | “0.30 (0.15, 0.59)” | Not applicable |
First-line combination in inhibitor-naive disease: PROpel publication
“We conducted a double-blind, phase 3 trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC in the first-line setting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At this planned primary analysis at the first data cutoff, median ibPFS was significantly longer in the abiraterone and olaparib arm than in the abiraterone and placebo arm (24.8 vs. 16.6 months; hazard ratio, 0.66; 95% confidence interval [CI], 0.54 to 0.81; P<0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
First-line combination: talazoparib with enzalutamide
| Outcome (TALAPRO-2, HRR gene-mutated) | Talazoparib with enzalutamide (N=200) | Placebo with enzalutamide (N=199) |
|---|---|---|
| Median rPFS by BICR, months (95% CI) | “NR (21.9, NR)” | “13.8 (11.0, 16.7)” |
| rPFS hazard ratio (95% CI) | “0.45 (0.33, 0.61)” | Not applicable |
| Median OS, months (95% CI) | “45.1 (35.4, NR)” | “31.1 (27.3, 35.4)” |
| OS hazard ratio (95% CI) | “0.62 (0.48, 0.81)” | Not applicable |
First-line combination: TALAPRO-2 all-comers publication
“TALAPRO-2 is a randomised, double-blind, phase 3 trial of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line therapy in men (age ≥18 years [≥20 years in Japan]) with asymptomatic or mildly symptomatic mCRPC receiving ongoing androgen deprivation therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the planned primary analysis, median rPFS was not reached (95% CI 27·5 months-not reached) for talazoparib plus enzalutamide and 21·9 months (16·6-25·1) for placebo plus enzalutamide (hazard ratio 0·63; 95% CI 0·51-0·78; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
First-line combination: niraparib with abiraterone acetate
| Outcome (MAGNITUDE, BRCA-mutated subgroup) | Niraparib with abiraterone acetate (N=113) | Placebo with abiraterone acetate (N=112) |
|---|---|---|
| Median rPFS, months (95% CI) | “16.6 (13.9, NE)” | “10.9 (8.3, 13.8)” |
| rPFS hazard ratio (95% CI) | “0.53 (0.36, 0.79)” | Not applicable |
Guideline statements on first-line PARP inhibitor combinations
PSMA-targeted radioligand therapy
FDA-approved indication in androgen pathway modulation-resistant prostate cancer
Taxane-naive disease after one ARPI: trial population and crossover
Taxane-naive disease after one ARPI: efficacy versus a change in ARPI
| Outcome | Lutetium Lu 177 vipivotide tetraxetan | Change in ARPI | Hazard ratio (95% CI) |
|---|---|---|---|
| Radiographic progression-free survival, median months (95% CI) | “9.3 (7, NE)” | “5.6 (4, 6)” | “0.41 (0.29, 0.56)” |
| Overall survival, median months (95% CI) | “24.5 (19.5, 28.9)” | “23.1 (19.6, 25.5)” | “0.91 (0.72, 1.14)” |
Taxane-naive disease after one ARPI: updated radiographic progression-free survival and safety
“In an updated analysis at the third interim overall survival analysis, the HR for rPFS was 0·49 (95% CI, 0·39–0·61; median rPFS, 11·60 months [95% CI, 9·30–14·19] vs 5·59 [4·21–5·95]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of grade 3–5 adverse events was lower with 177 Lu-PSMA-617 vs ARPI change (81/227 [36%] vs 112/232 [48%]; grade 3–4, 80/227 [35%] vs 111/232 [48%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease after ARPI and taxane chemotherapy: overall survival versus best standard of care
| Outcome | Lutetium Lu 177 vipivotide tetraxetan plus best standard of care | Best standard of care | Hazard ratio (95% CI) |
|---|---|---|---|
| Overall survival, median months (95% CI) | “15.3 (14.2, 16.9)” | “11.3 (9.8, 13.5)” | “0.62 (0.52, 0.74)” |
Disease after ARPI and taxane chemotherapy: imaging-based progression-free survival and adverse events
“177 Lu-PSMA-617 plus standard care significantly prolonged, as compared with standard care, both imaging-based progression-free survival (median, 8.7 vs. 3.4 months; hazard ratio for progression or death, 0.40; 99.2% confidence interval [CI], 0.29 to 0.57;” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of adverse events of grade 3 or above was higher with 177 Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparison with cabazitaxel after docetaxel
Myelosuppression
Guideline recommendations
Alpha-emitting radiopharmaceuticals
FDA-approved indication and dosing
Symptomatic bone-metastatic disease: trial population
Symptomatic bone-metastatic disease: overall survival versus placebo
| Analysis | Radium Ra 223 dichloride, median months (95% CI) | Placebo, median months (95% CI) | Hazard ratio (95% CI) |
|---|---|---|---|
| Interim analysis | “14.0 (12.1, 15.8)” | “11.2 (9.0, 13.2)” | “0.695 (0.552, 0.875)” |
| Updated analysis | “14.9 (13.9, 16.1)” | “11.3 (10.4, 12.8)” | “0.695 (0.581, 0.832)” |
Bone marrow suppression
Combination with abiraterone acetate
Combination with enzalutamide
Guideline recommendations
Autologous cellular immunotherapy
FDA-approved indication and dosing
Asymptomatic or minimally symptomatic disease: trial population
Asymptomatic or minimally symptomatic disease: overall survival versus control
| Study | Sipuleucel-T, median months (95% CI) | Control, median months (95% CI) | Hazard ratio | Hazard ratio 95% CI |
|---|---|---|---|---|
| Study 1 | “25.8 (22.8, 27.7)” | “21.7 (17.7, 23.8)” | “0.775” | “(0.614, 0.979)” |
Immune checkpoint inhibitors
FDA-approved tumor-agnostic indications
MSI-H or dMMR solid tumors: objective response in prostate cancer
| Tumor type | Patients | Objective response, n (%) | 95% CI | Duration of response, months |
|---|---|---|---|---|
| Prostate cancer | “8” | “1 (13%)” | “(0%, 53%)” | “24.5+” |
Prevalence of MSI-H or dMMR prostate cancer and response to PD-1 or PD-L1 blockade
“Among the 1033 patients who had adequate tumor quality for MSIsensor analysis (mean [SD] age, 65.6 [9.3] years), 32 (3.1%) had MSI-H/dMMR prostate cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eleven patients with MSI-H/dMMR castration-resistant prostate cancer received anti–PD-1/PD-L1 therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Six of these (54.5%) had a greater than 50% decline in prostate-specific antigen levels, 4 of whom had radiographic responses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab monotherapy in biomarker-unselected disease after docetaxel and endocrine therapy
“Cohorts 1 and 2 enrolled patients with RECIST-measurable PD-L1–positive and PD-L1–negative disease, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Objective response rate was 5% (95% CI, 2% to 11%) in cohort 1 and 3% (95% CI, < 1% to 11%) in cohort 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was 9.5 months in cohort 1, 7.9 months in cohort 2, and 14.1 months in cohort 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statements on biomarker testing
Bone-targeted agents
FDA-approved indications
Denosumab versus zoledronic acid in castration-resistant disease with bone metastases
“Median time to first on-study skeletal-related event was 20·7 months (95% CI 18·8–24·9) with denosumab compared with 17·1 months (15·0–19·4) with zoledronic acid (hazard ratio 0·82, 95% CI 0·71–0·95; p=0·0002 for non-inferiority; p=0·008 for superiority).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More events of hypocalcaemia occurred in the denosumab group (121 [13%]) than in the zoledronic acid group (55 [6%]; p<0·0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Osteonecrosis of the jaw occurred infrequently (22 [2%] vs 12 [1%]; p=0·09).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zoledronic acid versus placebo in metastatic prostate cancer
| Study | Patients with a skeletal-related event, zoledronic acid 4 mg | Patients with a skeletal-related event, placebo | Median days to first skeletal-related event, zoledronic acid 4 mg | Median days to first skeletal-related event, placebo | Hazard ratio for first skeletal-related event (95% CI) |
|---|---|---|---|---|---|
| Prostate cancer study | “33%” | “44%” | “Not Reached” | “321” | “0.67 (0.49, 0.91)” |
Osteonecrosis of the jaw and hypocalcemia
Bone protection during ARPI and radium-223 treatment
Limitations of current therapies
Summary
- All patients treated for mCRPC eventually progress. The EAU guideline advises avoiding sequencing of androgen receptor-targeted agents, citing cross-resistance that it extends from abiraterone to apalutamide and darolutamide.
- Activity of a second ARPI is limited. In a randomized crossover trial, PSA responses to second-line therapy occurred in 26 of 73 participants (36%) receiving enzalutamide and 3 of 75 (4%) receiving abiraterone. In a single-arm study of enzalutamide after at least 24 weeks of abiraterone, median radiographic progression-free survival (rPFS) was 8.1 months and the unconfirmed PSA response rate was 27% (48 of 181). In PLATO, adding abiraterone after PSA progression on enzalutamide did not prolong progression-free survival (5.7 vs 5.6 months; HR, 0.83; 95% CI, 0.61 to 1.12).
- In the control arms of randomized trials, median rPFS with a second ARPI was 3.7 months in CARD (after docetaxel), 3.6 months in PROfound cohort A (homologous recombination repair gene alterations), 4.5 months in the TRITON3 BRCA subgroup, and 5.59 months in PSMAfore (taxane-naive, third data cut-off), where 17% had a confirmed PSA decline of at least 50%. These figures are cross-trial. The PSMAfore investigators stated that a change in ARPI “has lesser clinical efficacy than taxanes”.
- Second ARPIs are nonetheless common in practice. In Medicare claims, novel hormonal therapy followed by a different novel hormonal therapy was the most common first- to second-line sequence (33%), only 28% of men starting first-line novel hormonal therapy later received a different class, and 22% received no life-prolonging therapy after mCRPC diagnosis.
- Taxane chemotherapy carries toxicity: the cabazitaxel label reports serious adverse reactions in 39% of recipients and neutropenic deaths, and in CARD treatment discontinuations for adverse reactions occurred in 20% of cabazitaxel recipients and 8% of those receiving abiraterone or enzalutamide. In TROPIC, grade 3 or higher neutropenia occurred in 82% of cabazitaxel recipients.
- PSMA-targeted radioligand therapy requires PSMA-positive disease on PET imaging and delivery by providers licensed to handle radiopharmaceuticals; in VISION, 126 screened participants (12.6%) did not meet PSMA imaging criteria. In PSMAfore, median overall survival was 24.5 months with lutetium Lu 177 vipivotide tetraxetan and 23.1 months with a change in ARPI (HR, 0.91; 95% CI, 0.72 to 1.14); the publication reported crossover in 134 of 234 participants (57%) randomized to ARPI change, which “may have confounded” the overall survival analysis, and the label reports crossover in 141 participants (60%).
- Biomarker-directed therapies apply to subsets. Alterations in BRCA2, BRCA1, or ATM were found in 29 of 150 metastatic biopsies (19.3%), rucaparib is labeled only for BRCA-mutated disease, and in the TRITON3 ATM subgroup the rPFS hazard ratio was 0.95 (95% CI, 0.59 to 1.52). First-line PARP inhibitor combinations are recommended only for patients who did not previously receive an ARPI, and the olaparib-abiraterone trial excluded prior abiraterone. Microsatellite instability-high or mismatch repair-deficient disease was found in 32 of 1033 patients (3.1%); pembrolizumab produced a response in 1 of 8 patients with prostate cancer in the tumor-agnostic label, and objective response rates of 5% and 3% in PD-L1-positive and PD-L1-negative cohorts after docetaxel and endocrine therapy.
- Other options have restricted populations: radium-223 is labeled for symptomatic bone metastases without known visceral disease, is not recommended with abiraterone plus prednisone because of more fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%), and caused bone marrow failure or ongoing pancytopenia in 2% of recipients. The sipuleucel-T trial excluded visceral metastases and moderate to severe cancer pain; each of its 3 doses requires leukapheresis, and it did not significantly prolong time to disease progression in any phase 3 study. Bisphosphonates have shown no survival benefit in any prospective trial, and overall survival was similar with denosumab and zoledronic acid.
Progression on available treatments
Cross-resistance between androgen receptor pathway inhibitors
Radiographic progression-free survival with a change in ARPI
“A change in ARPI has lesser clinical efficacy than taxanes,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“median rPFS in the ARPI change group was 5·59 months at third data cut-off” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Use of sequential ARPI therapy in place of chemotherapy
“However, real-world data indicates that many patients do not receive taxane-based chemotherapy after progression on a first ARPI and instead switch to a second ARPI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Toxicity of taxane chemotherapy after ARPI
Eligibility and delivery requirements for PSMA-targeted radioligand therapy
“The eligibility criteria for PSMA imaging were not met in 126 patients (12.6%; those with no PSMA-positive lesions or ≥1 exclusionary PSMA-negative lesion) and were met in 869 patients (86.6%; those with ≥1 PSMA-positive lesion and no exclusionary PSMA-negative lesions);” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall survival with radioligand therapy before taxane chemotherapy
Eligibility for homologous recombination repair-directed therapy
Eligibility for checkpoint inhibitor therapy
Undertreatment in routine practice
“22% received no life-prolonging therapy after mCRPC, 78% received ≥1 line of therapy (LOT), 42% underwent ≥2 LOTs, and 20% had ≥3 LOTs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data highlight the dramatic undertreatment that occurs for mCRPC patients, particularly for therapies beyond NHTs as well as the common use of sequential NHTs in real-world data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
Rinzimetostat is investigational; ORIC has not submitted for or obtained regulatory approval for any product candidate. Himalayas-1 (NCT07723248) is a global, randomized, open-label phase 3 trial of rinzimetostat plus darolutamide compared with a prespecified physician’s choice of an ARPI or docetaxel in approximately 600 participants with mCRPC previously treated with abiraterone. The trial requires disease progression on abiraterone in the metastatic castration-sensitive or first-line mCRPC setting, permits docetaxel for castration-sensitive disease, and excludes prior cytotoxic chemotherapy otherwise, radioligand therapy, and apalutamide, darolutamide, or enzalutamide; it was recruiting with an actual start of 2026-08-03 and an estimated primary completion of 2028-03. The proposed position is therefore after abiraterone and before chemotherapy, radioligand therapy, or a second ARPI for castration-resistant disease. A separate phase 3 trial evaluates another PRC2 inhibitor, mevrometostat, plus enzalutamide against physician’s choice of enzalutamide or docetaxel in mCRPC after at least 12 weeks of abiraterone.
Both components of the regimen are oral: participants are randomized 1:1 to rinzimetostat 400 mg once daily plus darolutamide 600 mg twice daily, while the docetaxel control is given at 75 mg/m2 intravenously every 21 days for up to 10 cycles. The darolutamide label lists non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer (alone or with docetaxel), without mCRPC, and requires a concurrent gonadotropin-releasing hormone agonist or antagonist or prior bilateral orchiectomy.
ORIC estimated the U.S. population at approximately 17,000 men per year with mCRPC previously treated with abiraterone and an addressable market of more than $3.5 billion, reported that abiraterone, the leading ARPI, has maintained more than 50% market share of new prescriptions over the last five years, and stated that this market “lacks oral, well-tolerated therapies with meaningful efficacy”. ORIC is also exploring rinzimetostat in other populations, including post-AR inhibitor mCRPC, and lists a second phase 3 trial (Himalayas-2) with apalutamide. These are company statements that are not peer reviewed.
The regimen pairs rinzimetostat with a second ARPI in a setting where the EAU guideline advises avoiding sequencing of androgen receptor-targeted agents, recommends chemotherapy after an ARPI, and states that an ARPI-ARPI sequence “should never be the preferred option”. In U.S. practice, a second ARPI is nonetheless the most frequent choice: 459 of 804 ARPI-experienced patients with mCRPC (57.1%) received another ARPI and 192 (23.9%) chemotherapy; among 1,519 Medicare patients with prior novel hormonal therapy, 70% received novel hormonal therapy as first-line mCRPC treatment, 7% chemotherapy, and 13% no subsequent life-prolonging therapy. In another real-world cohort, 48.4% received a sequential ARPI and 35% docetaxel as index therapy, abiraterone followed by docetaxel (16.1%) and abiraterone followed by enzalutamide (10.9%) were the most common sequences, and taxane use was 42% to 46% with ECOG performance status 0 to 1 and 29% with ECOG 2 or higher. The initial ARPI is increasingly given before castration resistance: in pre-mCRPC settings in 82.6% of patients in that cohort, and as ARPI-only treatment before mCRPC diagnosis in 34.8% of a U.S. cohort in 2023, compared with 10.3% in 2018.
Proposed position after abiraterone and before chemotherapy for castration-resistant disease
Oral once-daily regimen compared with oral and intravenous control therapies
Darolutamide labeled indications do not include metastatic castration-resistant disease
Company statement of the anticipated population and unmet need
Further populations under evaluation by the company
Guideline position of androgen receptor pathway inhibitor sequencing and chemotherapy
US real-world treatment after a prior androgen receptor pathway inhibitor
“Among 804 ARPI-experienced mCRPC patients, 459 patients (57.1%) received another ARPI as their index therapy and 192 (23.9%) received chemotherapy as their index therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this real-world analysis, more than half of patients attempted at least 1 additional ARPI in the mCRPC setting, despite prior treatment with ARPIs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with baseline NHT use (1,519 patients), 70% received 1 L NHT after mCRPC diagnosis, 7% chemotherapy, 6% combination & other, 2% sipuleucel-T, 1% radium-223, and 13% had no subsequent life-prolonging therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As index line, most patients received another (sequential) ARPI (48.4%) or docetaxel (35%). Most common sequences from preindex to index therapy were abiraterone→docetaxel (16.1%) and abiraterone→enzalutamide (10.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with ECOG score 0-1 more commonly received taxane therapy (42%-46%) than those with ECOG score ≥ 2 (29%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Shift of androgen receptor pathway inhibitor use into castration-sensitive disease
“The use of ARPi-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over the study course, the majority (76.8%) of patients received an ARPi as 1L treatment for mCRPC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Competing PRC2 inhibitor combination in the same treatment position
Heterogeneity of treatment effect
Liver metastases and overall survival in castration-resistant disease
“Men with liver metastases had the worst median OS (13.5 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In summary, men with mCRPC treated with docetaxel who have liver metastases had worse OS duration than men with lung metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 1b landmark radiographic progression-free survival by prior therapy
| Cohort (rinzimetostat 400 mg once daily plus darolutamide) | Landmark rPFS at 3, 4, and 5 months | Median follow-up |
|---|---|---|
| Previously treated with abiraterone | “93%, 84%, and 84% at 3, 4, and 5 months” | “4.9 months” |
| Previously treated with AR inhibitors | “93%, 85%, and 85% at 3, 4, and 5 months” | “4.8 months” |
Phase 1b safety in the broader post-ARPI population
Phase 1b ctDNA responses by androgen receptor genotype and partner agent
Prior androgen receptor pathway inhibitor exposure and outcomes with an ARPI versus cabazitaxel
“Prior ARPI exposure (in 37.7%) predicted inferior outcomes on ARPIs but not on cabazitaxel.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A high baseline ctDNA fraction correlated with reduced rPFS and OS; plasma AR copy number status was not associated with outcomes, but PTEN alterations were linked with shorter OS (hazard ratio: 1.9, multivariable p = 0.02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Duration of response to the first androgen receptor pathway inhibitor
Circulating tumor DNA fraction as a prognostic and predictive factor
“Baseline circulating tumour DNA (ctDNA) fraction above the cohort median and on-treatment ctDNA increase were associated with shorter time to progression (HR = 2.38, P < 0.001; HR = 4.03, P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ctDNA abundance was prognostic independent of clinical features, and holds promise as a stratification biomarker.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes by treatment received before castration resistance
“In the overall population, median TTPD was 12.1 months and trended lower for patients who had received prior ARPi-only treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall median OS was 24.6 months and trended lower for patients who received prior ARPi only or both prior ARPi and taxane.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
Multidisciplinary team management
Germline and somatic genomic testing
“Patients with metastatic prostate cancer should undergo both germline and somatic DNA sequencing using panel-based assays.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“this panel recommends considering retesting in patients whose results were previously negative or uninformative, and to consider either a metastatic biopsy or ctDNA when a significant change in clinical status occurs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Confirmed castrate testosterone and continued androgen deprivation
Baseline assessment and monitoring during treatment
Bone health with bone-targeted agents
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Himalayas-1 objective and endpoints
Company-stated therapeutic goal
Company benchmark for approved post-ARPI therapies
Control-arm outcomes with an alternative ARPI or docetaxel after a first ARPI
US real-world outcomes after a prior androgen receptor pathway inhibitor
“In the overall population, median time on the index therapy and median time from index therapy to next therapy were 4.1 and 6.2 months, respectively. Median overall survival and radiographic progression-free survival from the initiation of index therapy were 15.1 and 7.0 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median time from start of 1 L to next LOT or end of follow-up was 13.7 months, 10.9 months from 2 L start, and 8.9 months from 3 L start.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median survival was 25.6 months after mCRPC and 23.4 months following treatment initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote